侵袭性垂体瘤治疗方法的研究进展

刘红艳; 谷伟军; 母义明

doi:10.3969/j.issn.2095-5227.2023.04.017

侵袭性垂体瘤治疗方法的研究进展

doi: 10.3969/j.issn.2095-5227.2023.04.017

解放军总医院第一医学中心内分泌科，北京　100853

基金项目: 北京市科委其他项目(Z201100005520014)

详细信息

作者简介:
刘红艳，女，博士。研究方向：内分泌与代谢疾病的基础与临床研究。Email: zliuhongyan@163.com

通讯作者:
母义明，男，博士，主任医师，教授，博士生导师。Email: muyiming@301hospital.com.cn

中图分类号: R736.4
计量
- 文章访问数: 279
- HTML全文浏览量: 66
- PDF下载量: 13
- 被引次数: 0
出版历程
- 收稿日期: 2022-04-28
- 网络出版日期: 2023-03-17
- 刊出日期: 2023-04-28

Research advances in treatment of aggressive pituitary adenomas

Department of Endocrinology, the First Medical Center, Chinese PLA General Hospital, Beijing 100853, China

More Information

Corresponding author: MU Yiming. Email: muyiming@301hospital.com.cn

摘要

摘要: 垂体瘤是最常见的颅内肿瘤，大多数属于良性肿瘤。少数肿瘤呈侵袭性生长，其特点为侵袭周围的解剖结构、对常规治疗抵抗、术后早期复发率高。目前，侵袭性垂体瘤的治疗仍然是一个挑战。本文从三个方面综述侵袭性垂体瘤的治疗进展：(1)标准的治疗方案为再手术治疗或放射治疗，能在一定程度降低激素分泌水平，但不能控制肿瘤进展；(2)替莫唑胺被推荐作为侵袭性垂体瘤的一线化疗药物，但只对部分患者有效；(3)肽受体放射性核素治疗、新的分子靶向药物(mTOR抑制剂和表皮生长因子受体抑制剂)和免疫检查点抑制剂已用于治疗侵袭性垂体瘤的临床研究，并且取得了一定的治疗效果，给侵袭性垂体瘤患者带来了希望。
- 侵袭性垂体瘤 /
- 治疗 /
- 替莫唑胺 /
- 分子靶向药物 /
- 免疫检查点抑制剂
Abstract: Pituitary adenomas, the most common intracranial tumors, are usually benign. However, they may invade the adjacent structures, named invasive pituitary adenomas. Such tumors are characterized by refractory to traditional treatment and higher rate of early recurrence. Up to now, it is still a challenge for clinicians to manage the patients with invasive pituitary adenomas. Standard treatments are repeat surgery or radiotherapy, which can control hypersecretion, but have poor efficacy on tumor progression. Temozolomide is recommended as first-line chemotherapy drug for aggressive pituitary tumors, but it is only effective for partial patients. Peptide receptor radionuclide therapy, novel molecular targeted agents (mTOR inhibitors and EGF inhibitors) and immunecheckpoint inhibitors (ICIs) have been used in clinical researches, bringing hopes to the patients with invasive pituitary adenomas.
- aggressive pituitary adenoma /
- invasion /
- temozolomide /
- molecular targeted agents /
- immune checkpoint inhibitors

HTML全文

参考文献(45)

[1]	Zhu HB,Li B,Li CZ,et al. The clinical features,recurrence risks and surgical strategies of bone invasive pituitary adenomas[J]. Clin Neurol Neurosurg,2021,201: 106455. doi: 10.1016/j.clineuro.2020.106455
[2]	Li CZ,Zhu HB,Zong XY,et al. Experience of trans-nasal endoscopic surgery for pituitary tumors in a single center in China:surgical results in a cohort of 2032 patients,operated between 2006 and 2018[J]. Clin Neurol Neurosurg,2020,197: 106176. doi: 10.1016/j.clineuro.2020.106176
[3]	Raverot G,Burman P,McCormack A,et al. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas[J]. Eur J Endocrinol,2018,178(1): G1-G24. doi: 10.1530/EJE-17-0796
[4]	Kobyakov GL,Chernov IV,Astafieva LI,et al. Use of chemotherapy in the treatment of aggresive pituitary adenomas[J]. Zh Vopr Neirokhir Im N N Burdenko,2020,84(1): 69-75. doi: 10.17116/neiro20208401169
[5]	Marques JVO,Boguszewski CL. Fertility issues in aggressive pituitary tumors[J]. Rev Endocr Metab Disord,2020,21(2): 225-233. doi: 10.1007/s11154-019-09530-y
[6]	Liu XS,Tang C,Wen GD,et al. The mechanism and pathways of dopamine and dopamine agonists in prolactinomas[J]. Front Endocrinol (Lausanne),2018,9: 768.
[7]	Rudman Y,Duskin-Bitan H,Manisterski Y,et al. Long-term response to cabergoline and multi-modal treatment in men with macroprolactinoma:does size really matter?[J]. Clin Endocrinol (Oxf),2021,95(4): 606-617. doi: 10.1111/cen.14541
[8]	Tang H,Cheng YJ,Huang JY,et al. Case report:temozolomide treatment of refractory prolactinoma resistant to dopamine agonists[J]. Front Endocrinol (Lausanne),2021,12: 616339. doi: 10.3389/fendo.2021.616339
[9]	Lasolle H,Ilie MD,Raverot G. Aggressive prolactinomas:how to manage?[J]. Pituitary,2020,23(1): 70-77. doi: 10.1007/s11102-019-01000-7
[10]	Araujo-Castro M,Pian H,Ruz-Caracuel I,et al. Presurgical somatostatin receptor ligand treatment does not affect tumor consistency in GH-secreting pituitary macroadenomas[J]. Endocr Connect,2021,10(1): 102-109. doi: 10.1530/EC-20-0414
[11]	Shimatsu A,Nakamura A,Takahashi Y,et al. Preoperative and long-term efficacy and safety of lanreotide autogel in patients with thyrotropin-secreting pituitary adenoma:a multicenter,single-arm,phase 3 study in Japan[J]. Endocr J,2021,68(7): 791-805. doi: 10.1507/endocrj.EJ20-0707
[12]	Tokutsu A,Okada Y,Torimoto K,et al. Response of thyrotropin-secreting pituitary tumors to preoperative lanreotide therapy. Report of two cases[J]. Neuro Endocrinol Lett,2020,41(1): 10-16.
[13]	Polat Korkmaz O,Gurcan M,Nuhoglu Kantarci FE,et al. The effects of pre-operative somatostatin analogue therapy on treatment cost and remission in acromegaly[J]. Pituitary,2019,22(4): 387-396. doi: 10.1007/s11102-019-00968-6
[14]	Yamamoto M,Nakao T,Ogawa W,et al. Aggressive cushing’s disease:molecular pathology and its therapeutic approach[J]. Front Endocrinol (Lausanne),2021,12: 650791. doi: 10.3389/fendo.2021.650791
[15]	Dai CX,Fan YH,Liu XH,et al. Predictors of immediate remission after surgery in cushing’s disease patients:a large retrospective study from a single center[J]. Neuroendocrinology,2021,111(11): 1141-1150. doi: 10.1159/000509221
[16]	Zhuang Z,Liu XH,Bao XJ,et al. Invasive ACTH-secreting pituitary macroadenoma in remission after transsphenoidal resection:a case report and literature review[J]. Medicine (Baltimore),2018,97(46): e13148.
[17]	Barbot M,Mondin A,Regazzo D,et al. Incretin response to mixed meal challenge in active cushing’s disease and after pasireotide therapy[J]. Int J Mol Sci,2022,23(9): 5217. doi: 10.3390/ijms23095217
[18]	Gadelha M,Bex M,Feelders RA,et al. Randomized trial of osilodrostat for the treatment of cushing disease[J]. J Clin Endocrinol Metab,2022,107(7): e2882-e2895. doi: 10.1210/clinem/dgac178
[19]	Witek P,Mehlich A,Stasiewicz A,et al. Osilodrostat - an emerging drug for the medical management of Cushing’s disease[J]. Endokrynol Pol,2022,73(2): 371-374. doi: 10.5603/EP.a2022.0009
[20]	Fleseriu M,Newell-Price J,Pivonello R,et al. Long-term outcomes of osilodrostat in Cushing’s disease:LINC 3 study extension[J]. Eur J Endocrinol,2022,187(4): 531-541. doi: 10.1530/EJE-22-0317
[21]	Cohen AC,Goldney DC,Danilowicz K,et al. Long-term outcome after bilateral adrenalectomy in Cushing’s disease with focus on Nelson’s syndrome[J]. Arch Endocrinol Metab,2019,63(5): 470-477.
[22]	Beck-Peccoz P,Giavoli C,Lania A. A 2019 update on TSH-secreting pituitary adenomas[J]. J Endocrinol Invest,2019,42(12): 1401-1406. doi: 10.1007/s40618-019-01066-x
[23]	Yoon JH,Choi W,Park JY,et al. A challenging TSH/GH co-secreting pituitary adenoma with concomitant thyroid cancer;a case report and literature review[J]. BMC Endocr Disord,2021,21(1): 177. doi: 10.1186/s12902-021-00839-x
[24]	Dai CX, Liu XH, Ma SH, et al. Management of refractory/aggressive pituitary adenomas review of current treatment options［M］//Da Silva Junior EB, Milano JB. Primary Intracranial Tumors. Rijeka: IntechOpen, 2019: 858.
[25]	McCormack A,Dekkers OM,Petersenn S,et al. Treatment of aggressive pituitary tumours and carcinomas:results of a European Society of Endocrinology (ESE) survey 2016[J]. Eur J Endocrinol,2018,178(3): 265-276. doi: 10.1530/EJE-17-0933
[26]	Park HH,Kim EH,Ku CR,et al. Outcomes of aggressive surgical resection in growth hormone-secreting pituitary adenomas with cavernous sinus invasion[J]. World Neurosurg,2018,117: e280-e289. doi: 10.1016/j.wneu.2018.06.012
[27]	Albano L,Losa M,Barzaghi LR,et al. Gamma knife radiosurgery for pituitary tumors:a systematic review and meta-analysis[J]. Cancers (Basel),2021,13(19): 4998. doi: 10.3390/cancers13194998
[28]	Wang ZX,Tang ZY,Zhao HL,et al. Treatment of recurrent undifferentiated pleomorphic sarcoma of infratemporal Fossa by surgery combined with carbon ion radiotherapy:one case report[J]. Front Surg,2021,8: 693774. doi: 10.3389/fsurg.2021.693774
[29]	Woznick WK,Engel A,Maas D. A rare case of metastatic transformation to pituitary carcinoma[J]. J. Endocr. Soc.,2021,5(Supplement_1): A565-A566.
[30]	Minniti G,Paolini S,Rea MLJ,et al. Stereotactic reirradiation with temozolomide in patients with recurrent aggressive pituitary tumors and pituitary carcinomas[J]. J Neurooncol,2020,149(1): 123-130. doi: 10.1007/s11060-020-03579-5
[31]	Luo M,Tan YH,Chen WL,et al. Clinical efficacy of temozolomide and its predictors in aggressive pituitary tumors and pituitary carcinomas:a systematic review and meta-analysis[J]. Front Neurol,2021,12: 700007. doi: 10.3389/fneur.2021.700007
[32]	Elbelt U,Schlaffer SM,Buchfelder M,et al. Efficacy of temozolomide therapy in patients with aggressive pituitary adenomas and carcinomas-a German survey[J]. J Clin Endocrinol Metab,2020,105(3): dgz211. doi: 10.1210/clinem/dgz311
[33]	Ishida A,Shichi H,Fukuoka H,et al. Temozolomide and capecitabine treatment for an aggressive somatotroph pituitary tumor:a case report and literature review[J]. Front Oncol,2022,12: 916982. doi: 10.3389/fonc.2022.916982
[34]	Das L,Gupta N,Dutta P,et al. Early initiation of temozolomide therapy may improve response in aggressive pituitary adenomas[J]. Front Endocrinol (Lausanne),2021,12: 774686. doi: 10.3389/fendo.2021.774686
[35]	Gao HL,Wang WQ,Yu XJ,et al. Patterns and predictors of pancreatic neuroendocrine tumor prognosis:are no two leaves alike?[J]. Crit Rev Oncol Hematol,2021,167: 103493. doi: 10.1016/j.critrevonc.2021.103493
[36]	Sorbye H,Kong G,Grozinsky-Glasberg S. PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3)[J]. Endocr Relat Cancer,2020,27(3): R67-R77. doi: 10.1530/ERC-19-0400
[37]	Giuffrida G,Ferraù F,Laudicella R,et al. Peptide receptor radionuclide therapy for aggressive pituitary tumors:a monocentric experience[J]. Endocr Connect,2019,8(5): 528-535. doi: 10.1530/EC-19-0065
[38]	Assadi M,Nemati R,Shooli H,et al. An aggressive functioning pituitary adenoma treated with peptide receptor radionuclide therapy[J]. Eur J Nucl Med Mol Imaging,2020,47(4): 1015-1016. doi: 10.1007/s00259-019-04578-z
[39]	Osterhage K,Rotermund R,Droste M,et al. Bevacizumab in aggressive pituitary adenomas - experience with 3 patients[J]. and,2021,129(3): 178-185.
[40]	Wang Y,He QW,Meng XJ,et al. Apatinib (YN968D1) and temozolomide in recurrent invasive pituitary adenoma:case report and literature review[J]. World Neurosurg,2019,S1878-S8750(19): 30044-0.
[41]	Zhang DY,Way JS,Zhang XH,et al. Effect of everolimus in treatment of aggressive prolactin-secreting pituitary adenomas[J]. J Clin Endocrinol Metab,2019,104(6): 1929-1936. doi: 10.1210/jc.2018-02461
[42]	Cooper O,Bonert VS,Rudnick J,et al. EGFR/ErbB2-targeting lapatinib therapy for aggressive prolactinomas[J]. J Clin Endocrinol Metab,2021,106(2): e917-e925. doi: 10.1210/clinem/dgaa805
[43]	Gnanalingham K, Zador Z, Kearney T, et al. Pituitary tumours［M］//Kirollos R, Helmy A, Thomson S, et al. Oxford Textbook of Neurological Surgery. Oxford: Oxford University Press, 2019: 299-320.
[44]	Duhamel C,Ilie MD,Salle H,et al. Immunotherapy in corticotroph and lactotroph aggressive tumors and carcinomas:two case reports and a review of the literature[J]. J Pers Med,2020,10(3): 88. doi: 10.3390/jpm10030088
[45]	Caccese M,Barbot M,Ceccato F,et al. Rapid disease progression in patient with mismatch-repair deficiency pituitary ACTH-secreting adenoma treated with checkpoint inhibitor pembrolizumab[J]. Anticancer Drugs,2020,31(2): 199-204. doi: 10.1097/CAD.0000000000000856